Back to Browse Journals » Patient Preference and Adherence » Volume 6

Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence

Authors Dupclay L, Eaddy M, Jackson J, Raju A, Shim A

Published Date July 2012 Volume 2012:6 Pages 499—507

DOI http://dx.doi.org/10.2147/PPA.S31417

Received 3 March 2012, Accepted 8 May 2012, Published 18 July 2012

Leon Dupclay,1 Michael Eaddy,2 James Jackson,2 Aditya Raju,2 Andrew Shim1

1Novartis Pharmaceuticals, East Hanover, NJ, 2Xcenda, Palm Harbor, FL, USA

Background: Patient medication adherence is multidimensional and poses significant concerns to health care professionals. One aspect of adherence is a patient forgetting to take their prescribed medication, which may be improved with reminder packaging (RP). The objective of this analysis was to assess the impact of RP on patient adherence to antihypertensive therapy.
Methods: This retrospective, propensity score-matched study evaluated patients switching to a single-pill combination of valsartan-hydrochlorothiazide in RP compared with patients remaining on the combination without reminder packaging (non-RP). Patients receiving combination therapy between April 1, 2009 and July 31, 2010 were eligible for inclusion. Patients were propensity score-matched on baseline adherence and background demographic variables, including comorbidities. Medication possession ratio, proportion of days covered, time to refill, and time to discontinuation were evaluated as primary measures of subsequent adherence and persistence.
Results: In a total of 9266 matched patients (4633 participants in both cohorts), adherence was significantly higher in the RP cohort compared with patients in the non-RP cohort (medication possession ratio, RP 80% versus non-RP 73%; proportion of days covered, RP 76% versus non-RP 63%; both P < 0.001). Refill timing was 10 days for RP patients versus 16 days for non-RP patients (P < 0.001). Similar trends were observed with respect to time to discontinuation (RP 196 days, non-RP 174 days; P < 0.001). A higher proportion of RP patients remained on therapy compared with non-RP patients, with patients in the RP group being 17% less likely to discontinue therapy compared with patients in the non-RP group (hazards ratio 0.833; 95% confidence interval 0.793–0.875).
Conclusion: This real-world assessment of differences in adherence and persistence rates demonstrated that patients receiving RP were more adherent and persistent with their treatment regimens.

Keywords: hypertension, reminder packaging, adherence, persistency

Corrigendum for this paper has been published

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Corrigendum

Dupclay L, Eaddy M, Jackson J, Raju A, Shim A

Patient Preference and Adherence 2012, 6:677-678

Published Date: 24 September 2012

Readers of this article also read:

Preparation and controlled-release studies of a protocatechuic acid-magnesium/aluminum-layered double hydroxide nanocomposite

Barahuie F, Hussein MZ, Hussein-Al-Ali SH, Arulselvan P, Fakurazi S, Zainal Z

International Journal of Nanomedicine 2013, 8:1975-1987

Published Date: 20 May 2013

Patterns and predictors of antihypertensive medication used 1 year after ischemic stroke or TIA in urban China

Xu J, Ju Y, Wang C, Wang Y, Liu L, Zhao X, Wang C, Wang A, Wang Y

Patient Preference and Adherence 2013, 7:71-79

Published Date: 18 January 2013

Cost-effective therapeutic hypothermia treatment device for hypoxic ischemic encephalopathy

Kim JJ, Buchbinder N, Ammanuel S, Kim R, Moore E, O'Donnell N, Lee JK, Kulikowicz E, Acharya S, Allen RH, Lee RW, Johnston MV

Medical Devices: Evidence and Research 2013, 6:1-10

Published Date: 3 January 2013

Comparative study of Mg/Al- and Zn/Al-layered double hydroxide-perindopril erbumine nanocomposites for inhibition of angiotensin-converting enzyme

Hussein Al Ali SH, Al-Qubaisi M, Hussein MZ, Ismail M, Zainal Z, Hakim MN

International Journal of Nanomedicine 2012, 7:4251-4262

Published Date: 3 August 2012

Patient perceptions of multiple sclerosis and its treatment

de Seze J, Borgel F, Brudon F

Patient Preference and Adherence 2012, 6:263-273

Published Date: 4 April 2012